#Tandem26
LightNews LightNews
eurofinsviracor.bsky.social
🔊 Listen to this exclusive interview with Dr. James L.M. Ferrara (Icahn School of Medicine at Mount Sinai) on Transplant Radio™ in booth 511 at #Tandem26!

🎧 Listen Now: lnkd.in/gESGm4R8

#agvhd #Tandem2026 #TransplantRADIO
February 7, 2026 at 6:50 PM
onclive.bsky.social
What is an overused oncology buzzword❓Experts at #Tandem26 weighed in with their own hot takes. 🤔

@astct.bsky.social @cibmtr.bsky.social #lymsm #leusm #melsm #oncology #hematology #AI

Check out the video here ➡️: www.onclive.com/shorts/overu...
www.onclive.com
February 7, 2026 at 6:11 PM
drmiguelperales.bsky.social
#tandem26 tradition - @astct.bsky.social Past President's Breakfast
February 7, 2026 at 6:07 PM
onclive.bsky.social
Watch 👀: Amrita Desai, MD, MPH of @ohsunews.bsky.social discusses lifileucel in metastatic melanoma at #Tandem26.

#melsm #oncology @astct.bsky.social @cibmtr.bsky.social

See the whole video here ➡️: onclive.com/shorts/tackl...
February 7, 2026 at 4:43 PM
sitcancer.bsky.social
Are you at #Tandem26 Meetings? Stop by booth T225 to learn more about SITC’s 41st Annual Meeting! #SITC26 is the perfect opportunity to share your research, learn about the latest in immuno-oncology and network with experts in the field.
February 7, 2026 at 3:00 PM
nmdp-org.bsky.social
It's the final day to come see us at #Tandem26!
📍 Visit NMDP at Booth #T430 to connect with our team
➕ Complete the Lifesaver Loop by visiting our partners and learning of our impactful collaboration for a chance to win a prize!
February 7, 2026 at 1:30 PM
onclive.bsky.social
WATCH: Kenneth Jin Chang Lim, MBBS, discusses a study investigating the use of dexamethasone prophylaxis to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy. @astct.bsky.social @cibmtr.bsky.social #Tandem26 #hematology #mmsm
www.onclive.com/view/dr-lim-...
www.onclive.com
February 7, 2026 at 2:23 AM
onclive.bsky.social
WATCH: Peter Riedell, MD, discusses the long-term efficacy of tisagenlecleucel in the third-line setting in patients with relapsed/refractory follicular lymphoma. @astct.bsky.social @cibmtr.bsky.social #Tandem26 #lymsm #hematology
www.onclive.com/view/dr-ried...
www.onclive.com
February 7, 2026 at 2:20 AM
onclive.bsky.social
Thanks to Dr Alfonso Molina, of @stanfordhealthcare.bsky.social, for joining us at #Tandem26 to share findings with Orca-T and allogeneic CAR-T cell therapy in B-ALL! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #leusm #hematology
www.onclive.com/conference/tct
February 7, 2026 at 2:00 AM
onclive.bsky.social
Thank you to Dr Amrita Desai, of @ohsunews.bsky.social, for stopping by during #Tandem26 to chat about real-world outcomes with lifileucel in melanoma! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #melsm
www.onclive.com/conference/tct
February 7, 2026 at 1:54 AM
onclive.bsky.social
A huge thanks to Dr Fernando Duarte, who sat down with us at #Tandem26 to discuss the use of allogeneic HCT in MDS in Brazil! Check out our site for more of today's exclusive meeting coverage! @astct.bsky.social @cibmtr.bsky.social #hematology
www.onclive.com/conference/tct
February 7, 2026 at 1:50 AM
onclive.bsky.social
What do you bring with you to every conference❓

Check out how experts at #Tandem26 answered. 😂

@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology

Watch the whole video here ➡️: www.onclive.com/shorts/hemat...
February 7, 2026 at 1:46 AM
hemedoc.bsky.social
#tandem26 Ferrara: JAKi facilitates tissue repair whereas steroids actually inhibit it (even though, yes, they do inhibit alloimmune responses). Ferrara’s goal is to move steroids to 2nd line tx for GVHD!
February 7, 2026 at 1:16 AM
hemedoc.bsky.social
#tandem26 Ferrara: thus far, most GVHD pox/treatment has focused on the intimation and persistence of the alloimmune response, but efforts to improve tissue resistance to damage are important. Eg, intestinal stem cells are damaged by GVHD cytokines. Rux prevents ISC apoptosis, but steroids don’t.
February 7, 2026 at 1:13 AM
hemedoc.bsky.social
#tandem26 Ferrara: refinement of biomarker + clinical sx based aGVHD stratification (MAGIC composite) now gives greater clarity in predicting outcomes at onset of aGVHD.
February 7, 2026 at 1:04 AM
hemedoc.bsky.social
#tandem26 Ferrara: beautiful and touching start to his E Don Thomas lecture by dedicating the talk to John Galvin, who we shockingly lost this past year at far, far too young an age.
February 7, 2026 at 12:58 AM
hemedoc.bsky.social
#tandem26 Unfortunately, I could only make the end of Stella Davies’s Bortin Lecture, but absolute respect to her for using her platform to speak out against the anti-immigrant, anti-democratic trajectory of our current course in America! “We can not sit this one out.” Agree 1000000% !!!
February 7, 2026 at 12:44 AM
cibmtr.bsky.social
A special congratulations to Dr. Stella Davies, our #Tandem26 Mortimer M. Bortin lecturer! It is our pleasure to now hear, “Waiting until Evening to See How Splendid the Day Has Been: Aging and Transplant at the Extremes of the Lifespan” this evening!
February 7, 2026 at 12:17 AM
cibmtr.bsky.social
Congratulations to CIBMTR Distinguished Service Award recipient, Dr. Parvez Ahmed at #Tandem26
February 7, 2026 at 12:08 AM
hemedoc.bsky.social
#tandem26 #bmtsm Rafati: in triple neg MF, TET2mut assoc with incr relapse and inferior OS, whereas TET2mut doesn’t affect outcomes with MF with canonical driver mutation.
February 6, 2026 at 11:48 PM
hemedoc.bsky.social
#tandem26 #bmtsm Rafati: triple neg MF have inferior alloHCT outcomes. Overall conventional high risk gene must not assoc w survival, but TP53m assoc w inferior outcome with any driver mutation.
February 6, 2026 at 11:45 PM
hemedoc.bsky.social
#tandem26 #bmtsm Rafati: driver mut found in 81.7%. 18% were triple neg. 94% found to have at least one somatic mut, 1/3 with ASXL1.
February 6, 2026 at 11:41 PM
hemedoc.bsky.social
#tandem26 #bmtsm Rafati: @cibmtr.bsky.social analysis of genetic predictors of alloHCT outcomes in myelofibrosis. Known high risk assoc w ASXL1+nonCALR/MPL muts. N=930 evaluated here w 95 gene assay.
February 6, 2026 at 11:38 PM
hemedoc.bsky.social
#tandem26 #bmtsm Popat: age and IPSS not correl w outcomes. TP53 mut status was assoc w 3yr PFS/OS 64% with TP53wt vs 50% with TP53m. Relapse >3x higher in TP53m. Impressive outcomes, but the high NRM is problematic, esp for TP53wt — ie at 12mos, only 6% relapse but OS 69% due to the high toxicity.
February 6, 2026 at 11:28 PM
hemedoc.bsky.social
#tandem26 #bmtsm Popat: N=50 w HR-MDS underwent CLADILLAC allo. Median age 63, 84% matched donors, 94% PBSC. 28% with TP53 abnormalities. 3yr PFS/OS both 60%, relapse 10%, NRM 30%.
February 6, 2026 at 11:22 PM